

PRIOR AUTHORIZATION POLICY

POLICY: Lipodystrophy – Egrifta Prior Authorization Policy

- Egrifta SV[®] (tesamorelin subcutaneous injection – Theratechnologies)

REVIEW DATE: 06/12/2024

OVERVIEW

Egrifta SV, an analog of human growth hormone-releasing factor, is indicated for the reduction of excess abdominal fat in patients with **human immunodeficiency virus (HIV) who have lipodystrophy**.^{1,3}

Limitations of use: 1) Long-term cardiovascular safety of Egrifta SV has not been established; 2) Not indicated for weight loss management; and 3) There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking Egrifta SV. In the pivotal trial, all patients had lipodystrophy and excess abdominal fat, evidenced by a waist circumference ≥ 95 cm (≥ 94 cm for female) and a waist-to-hip ratio ≥ 0.94 (≥ 0.88 for female).¹ Patients were required to be on a stable antiretroviral regimen for at least 8 weeks. Safety and effectiveness of Egrifta SV have been established in patients between 18 and 65 years of age.

Disease Overview

Lipodystrophy is the change in body fat which affects some patients with HIV infection, either due to HIV infection or due to medications to treat HIV.² Lipodystrophy is not a concern for most people who start HIV treatment now, because newer HIV medications are less likely to cause this effect.

Safety

Because the long-term cardiovascular safety and potential long-term cardiovascular benefit are not established, careful consideration should be given whether to continue Egrifta SV treatment in patients who do not show a clear efficacy response, as judged by the degree of reduction in visceral adipose tissue measured by waist circumference or computerized tomography scan. In the pivotal studies, efficacy of Egrifta SV was assessed at Week 26. Because Egrifta SV induces the release of endogenous growth hormone (a known growth factor) and increases serum insulin growth factor-1 (IGF-1), the benefits of treatment should be weighed against the increased risk of malignancies in patients who are HIV-positive. Since the effect of prolonged IGF-1 elevations on the development or progression of malignancies is unknown, monitor IGF-1 levels closely during Egrifta SV therapy and consider discontinuation in patients with persistent elevations of IGF-1 levels (e.g., > 3 standard deviation scores), especially if the patient has not experienced a robust response. Egrifta SV should be used with caution in patients who develop glucose intolerance or diabetes; discontinuation of therapy should be considered for patients who do not show a clear efficacy response.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Egrifta SV. All approvals are provided for the duration noted below. When approvals are authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Egrifta SV as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Egrifta SV to be prescribed by or in consultation with a physician who specializes in the condition being treated. In the approval indication, as appropriate, an asterisk (*) is noted next to the specified gender. In this context, the specified gender is defined as follows: females/males are defined as

06/12/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

individuals with the biological traits of a woman/man, regardless of the individual's gender identity or gender expression.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Egrifta SV is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Lipodystrophy Associated with Human Immunodeficiency Virus (HIV) Infection. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv, and v):

i. Patient is ≥ 18 years of age; AND

ii. The medication is prescribed for the reduction of excess abdominal fat; AND

iii. Patient meets ONE of the following (a or b):

a) If male*, waist circumference is ≥ 95 cm (37.4 in) and waist-to-hip ratio is ≥ 0.94 ; OR

b) If female*, waist circumference is ≥ 94 cm (37 in) and waist-to-hip ratio is ≥ 0.88 ; AND

iv. Patient has been stable on an antiretroviral regimen for at least 8 weeks; AND

Note: Examples include antiretroviral regimens containing protease inhibitors, nucleoside reverse transcriptase inhibitors, and/or non-nucleoside reverse transcriptase inhibitors.

v. The medication is prescribed by or in consultation with an endocrinologist or a physician specializing in the treatment of HIV infection (e.g., infectious disease, oncology).

B) Patient is Currently Receiving Egrifta. Approve for 1 year if the patient has responded, as determined by the prescriber.

Note: Examples of a response include reduction in visceral adipose tissue measured by waist circumference or computed tomography (CT) scan.

* Refer to the Policy Statement.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Egrifta SV is not recommended in the following situations:

1. Abdominal Obesity in a Patient without Human Immunodeficiency Virus (HIV) Infection.

More data are needed. Egrifta SV has been studied in a very limited number of patients who have abdominal obesity without HIV infection.⁴ To be eligible for the published trial, patients were required to have a peak stimulated growth hormone no higher than 9 mcg/L on a standardized growth hormone-releasing hormone-arginine stimulation test. Patients (n = 60) were randomized in a 1:1 ratio to treatment with Egrifta SV 2 mg once daily or placebo. The primary endpoint was the change in visceral adipose tissue from baseline. Over 12 months (using last observation carried forward), visceral adipose tissue improved significantly in patients treated with Egrifta SV compared with placebo (net treatment effect vs. placebo: -35 [95% confidence interval: -58, -12]; P = 0.003). Treatment with Egrifta SV increased IGF-1 by 90%, decreased triglycerides by 20%, and decreased log C-reactive protein by 24% compared with placebo. There was no effect on total cholesterol, high-density lipoprotein cholesterol, or low-density lipoprotein cholesterol in the treatment groups.

2. **Human Immunodeficiency Virus (HIV)-Related Cachexia, Weight Loss, or Fat Distribution other than Lipodystrophy.** Egrifita SV has not been studied in these conditions.
3. **Patient is > 65 Years of Age.** There is no information on the use of Egrifita SV in patients > 65 years of age with HIV and lipodystrophy.¹
4. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Egrifita SV[®] injection [prescribing information]. Montreal, Quebec, Canada: Theratechnologies; February 2024.
2. HIV and Lipodystrophy. National Institute of Health Office of AIDS Research. Available at: [HIV and Lipodystrophy | NIH](#). Accessed on May 31, 2024.
3. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. *J Acquir Immune Defic Syndr*. 2010;53(3):311-322.
4. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. *J Clin Endocrinol Metab*. 2012;97(12):4769-4779.